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Background
Late-onset sepsis in newborn infants is defined as sepsis 
occurring after the first 72 hours of life and is a major 
cause of infant mortality [1]. Furthermore, these infec-
tions increase the length of hospital stay, add millions of 
dollars  in  excess  healthcare  costs  annually  and  are 
associated  with  poorer  neurodevelopmental  outcomes. 
Infants of any gestational age are susceptible to late-onset 
sepsis.  However,  very  low  birth  weight  infants  (those 
weighing  less  than  1,500  g)  are  particularly  vulnerable 
because  of  the  need  for  invasive  monitoring,  impaired 
host  defense  mechanisms,  limited  amounts  of  normal 
endogenous flora, reduced barrier function of neonatal 
skin  and  frequent  exposure  to  broad-spectrum  anti-
biotics. Most late-onset infections in newborn infants are 
classified  as  healthcare-associated  infections  because 
they  occur  while  these  infants  are  receiving  neonatal 
inten  sive care. The two most common presentations are 
catheter-associated bloodstream infections and ventilator-
associated  pneumonia.  The  diagnosis  of  healthcare-
associated  infections  is  problematic  because  of  the 
overlap  between  clinical  signs  associated  with  ‘normal’ 
physiological  disturbances  and  those  of  bacteremia  or 
fungemia.  Earlier  diagnosis  of  sepsis  in  critically  ill 
infants would enable timely administration of antibiotics 
and discontinuation of treatment in infants with a low 
probability of sepsis.
Biomarker discovery
The use of plasma proteomics in biomarker discovery has 
been met with limited success. A recent review of the 
subject by Lottspeich et al. [2] suggests several reasons 
for this, including individual heterogeneity due to genetic 
and  environmental  factors,  technical  complexity  of 
quanti  tative plasma protein analysis and lack of repro-
duci  bility in blood sampling specimen processing. Despite 
these limitations, Ng et al. [3] present an intriguing study 
using proteomic analysis to identify novel host-response 
biomarkers  for  early  diagnosis  of  late-onset  sepsis  and 
necrotizing enterocolitis in preterm infants. The authors 
used a rigorous scientific study design, comprising both a 
case-control discovery and initial validation phase and a 
secondary prospective cohort validation phase, in order 
to  minimize  the  inherent  systemic  biases  that  often 
plague  biomarker  discovery  trials.  Furthermore,  the 
discovery phase of this study [3] included a longitudinal 
analysis of candidate biomarkers to demonstrate reversal 
of  expression  patterns  over  time,  thereby  verifying  the 
pathophysiological  relevance  of  these  proteins.  Initial 
validation studies identified serum amyloid A (SAA) and 
apolipoprotein  C-II  as  the  most  promising  candidate 
markers. Both plasma proteins may be mechanistically 
linked to the disease process (lipoprotein modulation of 
host immune response) so are biologically plausible as 
candidate biomarkers. Because plasma concentrations of 
these biomarker proteins may be determined using high-
throughput  immunoassay  techniques,  incorporation  of 
diagnostic  tests  for  them  into  clinical  practice  is 
economically  and  technically  feasible.  A  diagnostic 
equation was created (the ApoSAA score) and validated 
both  statistically  (Hosmer-Lemeshow  goodness  of  fit 
test)  and  clinically  in  a  prospective  cohort  study.  The 
authors  [3]  used  this  score  to  stratify  very  low  birth 
weight  infants  by  risk  for  sepsis  and/or  necrotizing 
enterocolitis, and they developed clinical guidelines for 
the initiation and timely discontinuation of antibiotics for 
each risk category.
Abstract
The diagnosis of healthcare-associated infections is 
problematic because of the overlap between clinical 
signs associated with ‘normal’ physiological disturbances 
and those of bacteremia or fungemia. Earlier diagnosis 
of sepsis in critically ill infants would enable timely 
administration of antibiotics and discontinuation of 
treatment in infants with a low probability of sepsis. A 
recent study by Ng et al. identified two novel biomarkers 
for late-onset neonatal sepsis: the des-arginine variant of 
serum amyloid A and apolipoprotein C-II. These markers 
may be of value in the identification of neonates with 
bacteremia or fungemia.
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© 2010 BioMed Central LtdThere are some potential limitations of this study that 
warrant further investigation. Experimental data suggest 
that SAA levels may be affected by nutritional status and 
hepatic  function  [4,5].  In  addition,  infusion  of  lipid 
emulsions  in  parenteral  nutrition  has  been  associated 
with  modification  of  apolipoprotein  C-II  [6].  These 
poten  tial confounding variables are particularly proble-
matic  in  a  patient  population  in  which  parenteral 
nutrition, cholestatic liver disease and postnatal growth 
failure are very common.
Apolipoprotein C-II and serum amyloid A
It is interesting that Ng et al. [3] identified two markers of 
late-onset  sepsis  involved  in  lipid  metabolism.  Serum 
amyloid  A  proteins  are  a  family  of  apolipoproteins 
associated with high-density lipoprotein in plasma; apo-
lipo  protein  C-II  is  responsible  for  activation  of  lipo-
protein  lipase.  High-density  lipoproteins  have  been 
shown to bind bacterial cell wall components, including 
lipoteichoic acid and endotoxin [7,8]. That suggests a role 
for lipoproteins in modulating the immune response. It is 
well  known  that  circulating  levels  of  free  fatty  acids, 
triglycerides and cholesterol are increased during sepsis. 
This response is beneficial to the infected host because 
lipids  provide  an  alternative  energy  source  for  injured 
tissues. The synthesis of apolipoproteins is increased in 
the liver with sepsis; however, gene expression of lipo-
protein  lipase  is  downregulated  by  tumor  necrosis 
factor-α (TNF-α) and other cytokines.
Serum  amyloid  A  is  a  generic  term  for  a  family  of 
proteins that is used as a marker of acute and chronic 
inflammation  [9,10].  The  dominant  isotype  (SAA1) 
consists of at least five allelic variants. SAA is believed 
to be a more sensitive indicator of inflammation than 
the widely used C-reactive protein. Expression of SAA 
is  principally  regulated  at  the  transcriptional  level  by 
cytokines  (TNF-α  and  interleukins  1  and  6)  or 
glucocorticoids. SAA levels peak on the third day after a 
sepsis episode and return to baseline approximately 4 
days later. Several other investigators have studied the 
utility of SAA in the diagnosis of late-onset sepsis [11]. 
SAA  is  believed  to  rise  more  rapidly  than  C-reactive 
protein and may have a better prognostic value during 
the first 24 hours after sepsis onset. Furthermore, SAA 
has  a  high  negative  predictive  value  and,  therefore, 
might  be  useful  in  identifying  infants  with  a  low 
probability of sepsis. The des-arginine variant of SAA, 
used  by  Ng  et  al.,  has  been  investigated  in  other 
infectious diseases [12], but not previously in neonatal 
sepsis. Apolipoprotein C-I has been shown to correlate 
with  mortality  in  adults  with  sepsis,  but  not 
apolipoprotein C-II. The study by Ng et al. [3] is the first 
to investigate apolipoprotein C-II in neonatal sepsis and 
necrotizing enterocolitis.
Conclusions
Blood culture remains the diagnostic gold standard for 
late-onset sepsis. However, clinicians frequently rely on 
screening  tests,  such  as  the  white  blood  cell  count, 
immature to total neutrophil ratio and C-reactive protein, 
to guide decisions regarding initiation or discontinuation 
of antimicrobial therapy. Because of the morbidity and 
potential  mortality  associated  with  late-onset  sepsis, 
screen  ing tests with high sensitivity and negative predic-
tive value are most valuable because all infected infants 
must be identified, and infants without sepsis should be 
spared  antimicrobial  therapy.  The  extraordinarily  high 
sensitivity and negative predictive value of the ApoSAA 
score  proposed  by  Ng  et  al.  [3]  make  this  screening 
strategy  an  appealing  option.  However,  the  generaliza-
bility of this tool to wider patient populations remains 
unknown.  External  validation  studies  assessing  the 
perfor  mance  of  these  biomarkers  in  other  institutions 
and in infants of varying gestational ages are necessary 
before  widespread  adoption  into  clinical  practice  is 
considered.
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